Gastroesophageal cancer Header
opdivo-dtc-util-nav

Indications

Prescribing Information

Next Page Icon

Medication Guide

Next Page Icon
Potential OPDIVO® (nivolumab) user wakesurfing with his dog.
Potential OPDIVO® (nivolumab) user wakesurfing with his dog.

Clinical trial results for
previously treated
advanced esophageal
squamous cell cancer

For people with previously treated advanced
esophageal squamous cell cancer

Actor portrayal.

An FDA-approved immunotherapy that helped people live longer compared to chemotherapy

About the clinical trial

In a clinical trial of 419 people with advanced esophageal squamous cell cancer that had been previously treated with fluoropyrimidine- and platinum-based chemotherapy, 210 people were given OPDIVO and 209 people were given either docetaxel or paclitaxel chemotherapy.

People given OPDIVO lived longer compared to chemotherapy

At 11 months, half the people given OPDIVO®  were alive.
OPDIVO

Half the people were alive

At 8 months, half the people given a placebo were alive.
Chemotherapy

Half the people were alive

In the clinical trial, people given OPDIVO had a 23% lower risk of dying than those given docetaxel or paclitaxel chemotherapy.

There was no significant difference between the two treatments in the percentage of patients who responded to treatment and in the length of time that patients lived without their tumors worsening.

OPDIVO will not work for everyone. Individual results may vary.

Hands exploring how OPDIVO® (nivolumab) works and learning how this treatment may help fight cancer.

How treatment works

See how this treatment may help your body fight cancer

OPDIVO® (nivolumab) side effects.

Side effects

View side effects of treatment and learn how to manage them

Nurse monitoring a gentleman's infusion of OPDIVO® (nivolumab) immunotherapy treatment.

Getting an infusion

See your recommended treatment plan and what to expect from an infusion

For adults with previously treated advanced esophageal squamous cell cancer

OPDIVO® (nivolumab) is a prescription medicine used to treat adults with cancer of the tube that connects your throat to your stomach (esophageal cancer) if your esophageal cancer is a type called squamous cell carcinoma, and cannot be removed with surgery, and has come back or spread to other parts of the body after you have received chemotherapy that contains fluoropyrimidine and platinum.

It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.

It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.